Why Was Heidi Overton’s FDA Nomination Withdrawn? What Happened and Who Leads the Agency Now

The White House withdrew Dr. Heidi Overton’s nomination to be Commissioner of the U.S. Food and Drug Administration (FDA) on November 17, 2026, one day before a scheduled Senate Health, Education, Labor, and Pensions (HELP) Committee vote. A senior administration official told Axios she “lacks the support on the Hill to move forward with her confirmation.” Reuters, citing three people familiar with the decision, also attributed it to insufficient congressional support.

Overton was never confirmed, and Kyle Diamantas remains the acting FDA commissioner. The withdrawal does not itself change any FDA-approved drug, vaccine recommendation or existing federal regulation.

Heidi Overton FDA Nomination Withdrawal: Quick Facts

DetailVerified information
NomineeDr. Heidi Overton, deputy director of the White House Domestic Policy Council
PositionCommissioner of Food and Drugs
Nominated byPresident Donald Trump
Nomination announcedAugust 19, 2026
Confirmation hearingSeptember 24, 2026
Scheduled committee voteNovember 18, 2026
Nomination withdrawnNovember 17, 2026
Senate committeeHealth, Education, Labor, and Pensions (HELP)
Committee chairmanSenator Bill Cassidy, Republican of Louisiana
Main controversiesChildhood vaccine policy, abortion medication (mifepristone), flavored vapes, management experience, independence from the White House and HHS
Current FDA leaderKyle Diamantas, acting commissioner
Replacement nomineeNone formally announced
Effect on FDA approvals and rulesNo automatic change

Why Did the White House Withdraw Heidi Overton’s FDA Nomination?

The administration’s stated reason is lack of Senate support. The HELP Committee had a narrow Republican majority, and none of its Democrats were expected to back her, so one or two Republican defections could have stalled her. CBS News reported she was struggling to find enough Republican votes. Reuters reported that some Trump officials began to doubt her support after Republicans suffered sweeping losses in this month’s midterm elections.

Several overlapping disputes surrounded the nomination. Reporting does not establish that any single one was decisive, and the White House has not described its private discussions.

Did Childhood Vaccine Policy and Senator Bill Cassidy’s Concerns Sink the Overton Nomination?

Cassidy, a physician and the committee chairman, said in August that he had “strong concerns,” citing her lack of managerial experience and her role in an August 2026 executive order on childhood vaccine scheduling, which he called “almost disqualifying.” The order, signed August 10, called for childhood vaccine shots to be spaced out into separate visits.

At her September 24 hearing, Cassidy asked whether the MMR vaccine is safe and effective. Overton said it was, but when he asked whether that meant she disagreed with President Trump’s claim that the vaccine was “potentially quite lethal,” she did not answer directly. Days before the withdrawal, Cassidy said, “I still have questions,” and that he could not predict the outcome of the vote. Reuters described Cassidy as the outgoing chairman, having lost his re-election bid.

Did Mifepristone and Abortion Policy Contribute to the Overton Withdrawal?

Mifepristone was a second flashpoint, and it drew criticism from opposite directions. Democrats, including Senator Patty Murray, criticized Overton’s anti-abortion record and her criticism of looser mifepristone dispensing rules. Anti-abortion groups pressed from the other side. On November 11, Susan B. Anthony Pro-Life America urged the Senate to delay her confirmation until the administration committed to restore in-person dispensing for mifepristone and address flaws in the FDA’s safety study.

At her hearing, Overton acknowledged mifepristone had met FDA safety and effectiveness determinations and declined to prejudge the agency’s ongoing review. The withdrawal does not by itself restrict or change access to mifepristone. The FDA is separately reviewing the drug, and findings are reportedly expected around March 2027.

Did Flavored Vapes and Questions About Management Experience Play a Role?

Senator Susan Collins sought answers on the FDA’s May authorization of fruit-flavored vapes, which Overton defended at her hearing by pointing to evidence that flavored vapes could help some adults quit smoking. Critics asked whether flavored products attract young users. Cassidy and others also questioned whether she had the executive experience to lead an agency that Reuters says has lost more than 4,500 staff over the past year.

The White House defended her record when she was nominated, saying she had been integral to ensuring the administration’s policies were “grounded in Gold Standard Science,” and Trump called her “a ROCKSTAR in my administration.” Some Make America Healthy Again supporters also opposed her, according to reporting, though the specific criticisms are political claims, not findings of misconduct.

Who Is Heidi Overton?

Dr. Heidi Overton is a physician and health policy adviser who served as a deputy director of the White House Domestic Policy Council in Trump’s second term. She is a Gallup, New Mexico native who attended the University of New Mexico School of Medicine, was a White House Fellow, holds a Ph.D. in Clinical Investigations from Johns Hopkins, and worked with the America First Policy Institute. She had never served as FDA commissioner. Trump picked her to succeed Dr. Marty Makary, who left in May 2026.

Related article: KJ Biermann Case, Prosecutors Oppose Juvenile Court Transfer and Cite 16 Prior Allegations

Why Was Heidi Overton's FDA Nomination Withdrawn? What Happened and Who Leads the Agency Now

Who Is Running the FDA After Heidi Overton’s Withdrawal?

Kyle A. Diamantas, J.D., remains the acting FDA commissioner. He took over after Makary’s departure and was previously the agency’s deputy commissioner for food. The FDA continues to operate under existing authority, and its scientific centers, inspectors and reviewers keep working. A lack of a Senate-confirmed leader can affect long-term priorities and management but does not suspend FDA operations. See the FDA leadership page.

How Does Federal Law Govern the Appointment of an FDA Commissioner?

Under 21 U.S.C. § 393(d)(1), the president appoints the commissioner with the advice and consent of the Senate. The usual steps are nomination, committee hearing and vote, then a full Senate vote. A president can withdraw a nomination at any time before confirmation, and the Senate does not have to reject a nominee for the White House to choose someone else.

What Is the Federal Vacancies Reform Act and How Does It Affect the Acting FDA Commissioner?

The Federal Vacancies Reform Act, principally 5 U.S.C. §§ 3345–3349d, lets certain officials temporarily perform the duties of a vacant Senate-confirmed office, subject to time limits that can be affected by pending nominations. Whether an acting official can continue depends on those statutory conditions and other appointment authorities. The withdrawal does not automatically invalidate actions taken by the acting commissioner. For more on appointments and congressional authority, see Can Trump Govern Without Congress? Presidential Powers Under a Divided Government Explained.

Who Could Replace Heidi Overton as FDA Commissioner?

No new nominee had been formally announced as of November 18, 2026. Reuters, citing two people, reported the White House is weighing Senator Roger Marshall of Kansas, a physician and former obstetrician who lost his re-election bid this month, as a possible replacement. Semafor, citing officials and a Republican aide, reported Republicans see a sitting senator as easier to confirm during the limited time left before Democrats take control of the Senate in January 2027. Consideration is not a nomination, and the White House has not commented. CBS News also reported that the White House has discussed candidates who could serve in an acting capacity, avoiding Senate confirmation.

Is There a Mifepristone Connection to the FDA Nomination Fight?

Mifepristone, approved by the FDA in 2000, is subject to federal safety requirements, including a Risk Evaluation and Mitigation Strategy, and the FDA has allowed certified providers and pharmacies to dispense it under specified conditions, including some telehealth arrangements. Patients should not assume that any ban or rule change took effect on November 17. For related court proceedings, see Mifepristone Supreme Court Ruling Explained, What the Supreme Court Just Decided and What Happens Next.

A separate government dispute over vaccine claims is covered in Florida AG Sues Pfizer Over COVID Vaccine Safety Claims, State Seeks $10,000 Per Violation and Return of Profits. It involves different legal claims and is unrelated to Overton’s confirmation.

What Does the FDA Leadership Change Mean for Americans?

Consumer concernImmediate effect of the withdrawal
FDA-approved prescription medicinesNo automatic change to approvals
Childhood vaccinesNo vaccine approval revoked
MifepristoneSeparate FDA review continues
Food recallsRecall and enforcement functions continue
Medical device approvalsExisting review processes continue
Flavored e-cigarettesExisting authorizations not automatically reversed
FDA leadershipKyle Diamantas continues as acting commissioner

The larger consequences depend on who is nominated next and what the FDA decides afterward.

Heidi Overton FDA Nomination Timeline

DateDevelopment
May 2026Marty Makary leaves the FDA commissioner position
August 10, 2026Trump signs an executive order on childhood vaccine scheduling, with Overton in the Oval Office
August 19, 2026Trump announces Overton as his nominee
September 24, 2026Overton testifies before the Senate HELP Committee
November 11, 2026Anti-abortion group urges the Senate to delay her confirmation
November 15, 2026Cassidy says he still has questions about the nomination
November 17, 2026White House withdraws the nomination
November 18, 2026Date of the scheduled committee vote
January 2027New Congress begins; Democrats take control of the Senate

Heidi Overton FDA Nomination: Frequently Asked Questions

Why was Heidi Overton’s FDA nomination withdrawn?

An administration official said she lacked the support needed on Capitol Hill. Disputes over childhood vaccines, mifepristone, flavored vapes and her management experience surrounded the nomination, and reporting does not identify one decisive reason.

Did the Senate reject Heidi Overton?

No. The nomination was withdrawn a day before the scheduled committee vote, so there was no committee or Senate vote.

Who is the FDA commissioner right now?

Kyle Diamantas is the acting commissioner. There is no Senate-confirmed commissioner.

Is Roger Marshall the new FDA commissioner?

No. He has been reported as a possible replacement under consideration, but no nomination has been announced.

Will the FDA change vaccine or abortion pill policy immediately?

No. The withdrawal is a personnel development, not a new regulation or drug-safety determination.

What Happens Next for the FDA?

The White House must decide whether and when to name another nominee, or whether to rely on acting leadership. A nomination would face the Senate process and a changed Senate in January 2027. In the meantime the FDA continues under Diamantas, and decisions on vaccines, mifepristone, vapes, drug approvals and food safety remain subject to existing laws and procedures. The next developments to watch are a formal replacement nomination, any change in acting leadership and substantive FDA regulatory decisions.

Bottom line: Heidi Overton’s November 17 withdrawal ended her bid for FDA commissioner before a Senate vote. Disagreements over vaccines, abortion policy and regulatory independence surrounded the decision, but it does not automatically change federal health law or existing FDA approvals.

Primary Sources and Official Records

  1. U.S. Senate HELP Committee, Nominations
  2. Senate HELP Committee, September 24, 2026 Confirmation Hearing
  3. Chairman Cassidy Remarks at Overton Confirmation Hearing
  4. FDA Commissioner Leadership Page
  5. 21 U.S.C. § 393
  6. 5 U.S.C. § 3345
  7. 5 U.S.C. § 3346
  8. Reuters, Trump Withdraws Heidi Overton as FDA Nominee, Sources Say
  9. Axios, White House Drops Heidi Overton’s FDA Nomination
  10. CBS News, Overton Confirmation Struggle
  11. Associated Press, White House Pulls FDA Nominee Heidi Overton

Disclaimer: This is general policy information, not legal or medical advice. Statements about the reasons for the withdrawal are attributed to the officials and news sources that made them. The withdrawal does not establish that anyone acted unlawfully.

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against Senate HELP Committee records and reporting from Reuters, Axios, CBS News and the Associated Press, as of November 18, 2026. Last Updated: November 18, 2026.

About the Author

Israr Ahmad is a legal content researcher with 4+ years of experience covering class action settlements and consumer rights cases. He has researched and published coverage of 2,500+ settlements using verified court records, settlement administrator filings, and government sources. Learn more about Israr.

Leave a Reply

Your email address will not be published. Required fields are marked *